 TOKYO, Jan. 10, 2023 PRNewswire Ajinomoto Co., Inc. Ajinomoto Co. today announced a license agreement with Exelixis, Inc. Exelixis to incorporate AJICAP, Ajinomoto Co.s proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis antibody-drug conjugate ADC programs. Exelixis is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery,... The post Ajinomoto and Exelixis Enter Into a Li... 